New Antiterrorism Tenets Trouble Scientists

Artwork: Anne MacNamara When the anthrax assaults of last fall transformed bioterrorism from theoretical possibility to reality, Congress wasted little time cranking out new laws that target laboratory operations. Within weeks of the attack on the World Trade Center, the USA Patriot Act whipped through Congress and became law, adding criminal sanctions to existing "biological weapons" statutes. A scant seven months later, the Public Health Security and Bioterrorism Response Act was signed, un

Written byPeg Brickley
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

When the anthrax assaults of last fall transformed bioterrorism from theoretical possibility to reality, Congress wasted little time cranking out new laws that target laboratory operations. Within weeks of the attack on the World Trade Center, the USA Patriot Act whipped through Congress and became law, adding criminal sanctions to existing "biological weapons" statutes. A scant seven months later, the Public Health Security and Bioterrorism Response Act was signed, underlining the need to control access to compounds and pathogens with weapons potential.

Critical questions about who will enforce the tougher laws and how they will go about it--enhanced reporting, surprise inspections, and regular audits--remain unclear. What is clear is that working scientists need to incorporate systems for keeping up with the pace of regulatory changes in their laboratory operations. No longer will an annual meeting with the university's environmental and safety advisors suffice. The Federal Register, where proposed and approved ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies